3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
59
Neoplasm Metastasis
24
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Adenocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Salivary Gland Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Solid Cancer
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Paclitaxel
13
pembrolizumab
8
Carboplatin
7
Cisplatin
5
Docetaxel
4
Brachytherapy
4
Pemetrexed
3
Gemcitabine
3
Doxorubicin
3
Biopsy
3
osimertinib
2
olaparib
2
niraparib
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Topotecan
2
Taxes
2
Standard of Care
2
Sentinel Lymph Node Biopsy
2
Saline Solution
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Nivolumab
2
Music Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Letrozole
2
Immunoglobulin G
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT06989112
2026-05-06
DE-01
AstraZeneca
Phase 3
Recruiting
600 enrolled